2012, Number 03
<< Back Next >>
MediSan 2012; 16 (03)
Incretins: a new therapeutic alternative for the glycometabolic control of the type 2 diabetes mellitus
Lazo RY, Lores DD
Language: Spanish
References: 29
Page: 445-451
PDF size: 188.51 Kb.
ABSTRACT
There are now newer treatments to control temporarily the blood glucose levels of most
patients with type 2 diabetes mellitus. Among these therapeutic agents are those that
replicate or potentiate the effect of incretins as agonists of glucagon-related peptide-1
and dipeptidyl peptidase-4 inhibitors, which have advantages such as eliminating
manifestations of hypoglycemia and neutral effect or decreased body weight.
Nevertheless, conclusive clinical data that demonstrate their effectiveness will be
provided over time.
REFERENCES
Puig Domingo M, Reviriego J. Las incretinas como nuevas dianas terapéuticas de la diabetes tipo 2. Rev Clin Esp. 2009;207(7):352-64.
Nogales Aguado P, Arrieta- Blanco F. Incretinas: nueva opción terapéutica para la diabetes mellitus tipo 2. JANO. 2010;(1756):62-6.
Centro Andaluz de Información de Medicamentos. Nuevos tratamientos para la diabetes mellitus tipo 2. ¿Qué aporta el efecto incretina?. Bol Ter Andal. 2009;25(2):5-8.
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-65.
Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes. Part II: Incretin based therapy and beyond. Circulation. 2008;117(4):574-84.
Stempa Blumenfeld O. Incretinas: Un nuevo paradigma en el tratamiento de la diabetes mellitus tipo 2. Rev Endocrinol Nutr. 2009;17(2): 84-90.
Giménez Pérez G. Fármacs amb efecte incretina en el tractament de la diabetes de tipus 2. Butll Inf Ter. 2008;20(4):19-24.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and metaanalysis. JAMA. 2007;298(2):194-206.
Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagons-like peptide 1 receptor for patients with inadequate glycemic control? Eur J Endocrinol. 2008;158(6):773-84.
Madsbad S. Treatment of type 2 diabetes with incretin based therapies. Lancet. 2009;373(9662):438-9.
11.Rachman J, Gribble FM, Borrow BA, Levy JC, Buchanan KD, Turner RC. Normalization of insulin responses to glucose by overnight infusion of glucagons-like peptide 1 (7- 36) amide in patients with NIDDM. Diabetes. 1996;45(11):1524-30.
Drucker DJ, Nauck MA. The incretin system: glucagons-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705.
Centro Andaluz de Información de Medicamentos. Exenatida (DCI). Ficha Noved Ter. 2009;(2).
14.Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. A randomized trial. Ann Intern Med. 2005;143(8):559-69.
Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333-48.
16.Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259-67.
Exenatide (Byetta): risk of acute pancreatitis. Drug Saf Update. [Internet] 2008 [citado 12 Jun 2010];1(10). Disponible en: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084982
18.Dungan K, Buse JB. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clinical Diabetes. 2005;23(2):56-62.
19.Ahmad SR, Swann J. Exenatide and rare adverse events. New Engl J Med. 2008;358(18):1970-2.
20.Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled in metformin alone: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194-205.
Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformina therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(10):959-69.
Pocock N. On The Horizon Post Launch Update - Sitagliptin in type 2 diabetes. NELM. 2007;(1).
23.Centro Andaluz de Información de Medicamentos. Vildagliptina (DCI). Ficha Noved Ter. [Internet]. 2008 [citado 10 Nov 2010];(5). Disponible en: http://www.juntadeandalucia.es/epescuelasaludpublica/web/documentos/FNT/00013952documento.pdf
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890-5.
Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes mailing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9(2):166-74.
Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10(11):1047-56.
Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double blind study. Diabetes Obes Metab. 2008;10(1):82-90.
Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Inhibidores de la dipeptidil peptidasa 4 (DPP-4) para la diabetes mellitus tipo 2. Biblioteca Cochrane Plus. [Internet]. 2008 [citado 16 May 2010];(4). Disponible en: http://www.updatesoftware.com/BCP/BCPGetDocument.asp?DocumentID=CD006739
29.Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type 2 diabetes. J Am Board Fam Med. 2006;19(6):612-20.